ProPhase Labs Narrows Loss to $0.51M Amid Strategic Divestiture

TL;DR

**PRPH is still bleeding cash from continuing operations, but the PMI sale offers a one-time lifeline; don't get fooled by the 'narrowed loss' headline.**

AI Summary

ProPhase Labs, Inc. (PRPH) reported a net loss of $0.51 million for the six months ended June 30, 2025, a significant improvement from the $12.42 million net loss in the prior year period. This improvement was largely driven by an $8.75 million gain from the disposal of discontinued operations, specifically the sale of PMI to JL Projects, Inc. on January 16, 2025. Revenues from continuing operations decreased to $2.68 million for the six months ended June 30, 2025, down from $3.86 million in the same period of 2024, reflecting a decline in its core business. The company's cash and cash equivalents plummeted from $678,000 at December 31, 2024, to $169,000 by June 30, 2025. Total assets decreased from $63.20 million to $42.04 million, while total liabilities also decreased from $55.85 million to $30.61 million. Strategic outlook includes continued pursuit of acquisitions and development of its genomics and biopharma segments, including the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test and DNA Complete's whole genome sequencing products.

Why It Matters

This filing reveals ProPhase Labs' ongoing pivot away from its struggling diagnostic testing services, evidenced by the sale of PMI and the significant gain from discontinued operations. While the net loss narrowed, the decline in continuing operations revenue signals challenges in its core business segments, impacting investor confidence. For employees, the shift could mean reallocation of resources and potential job changes as the company focuses on genomics and biopharma. Customers of the discontinued diagnostic services will need to find alternative providers. The broader market will watch if ProPhase can successfully transition into a profitable biotech and genomics player, especially given the competitive landscape in precision medicine and early cancer detection.

Risk Assessment

Risk Level: high — The company's cash and cash equivalents decreased significantly from $678,000 to $169,000 in six months, indicating a precarious liquidity position. Furthermore, net cash used in operating activities from continuing operations was $4.23 million for the six months ended June 30, 2025, demonstrating ongoing operational cash burn despite the gain from discontinued operations.

Analyst Insight

Investors should exercise extreme caution and conduct thorough due diligence. The significant cash burn from continuing operations and declining revenues suggest fundamental business challenges. Consider waiting for sustained profitability and positive cash flow from core operations before investing, as the one-time gain from the PMI sale masks underlying issues.

Financial Highlights

debt To Equity

2.67

revenue

$2.68M

operating Margin

N/A

total Assets

$42.04M

total Debt

$30.61M

net Income

-$0.51M

eps

N/A

gross Margin

N/A

cash Position

$169K

revenue Growth

-30.6%

Revenue Breakdown

Key Numbers

• $0.51M — Net Loss (for the six months ended June 30, 2025, a significant improvement from $12.42M loss in 2024)
• $2.68M — Revenues, net (from continuing operations for the six months ended June 30, 2025, down from $3.86M in 2024)
• $8.75M — Gain from disposal of discontinued operations (contributed to the reduced net loss for the six months ended June 30, 2025)
• $169K — Cash and cash equivalents (as of June 30, 2025, a decrease from $678K at December 31, 2024)
• $4.23M — Net cash used in operating activities - continuing operations (for the six months ended June 30, 2025, indicating ongoing cash burn)
• 41,541,205 — Common Stock Shares Outstanding (as of August 11, 2025, an increase from 29,874,029 at December 31, 2024)
• $42.04M — Total Assets (as of June 30, 2025, down from $63.20M at December 31, 2024)
• $30.61M — Total Liabilities (as of June 30, 2025, down from $55.85M at December 31, 2024)

Key Players & Entities

• ProPhase Labs, Inc. (company) — registrant
• JL Projects, Inc. (company) — purchaser of PMI
• PMI (company) — discontinued operations
• Nebula Genomics, Inc. (company) — wholly-owned subsidiary focused on genomics
• ProPhase BioPharma, Inc. (company) — wholly-owned subsidiary for drug development
• DNA Complete, Inc. (company) — wholly-owned subsidiary for whole genome sequencing
• Nasdaq Capital Market (regulator) — exchange where common stock is registered
• $0.51 million (dollar_amount) — net loss for six months ended June 30, 2025
• $12.42 million (dollar_amount) — net loss for six months ended June 30, 2024
• $8.75 million (dollar_amount) — gain from disposal of discontinued operations

FAQ

Risk Factors

• Deteriorating Cash Position [high — financial]: Cash and cash equivalents decreased significantly from $678,000 at December 31, 2024, to $169,000 at June 30, 2025. This sharp decline raises concerns about the company's short-term liquidity and ability to fund ongoing operations.
• Decline in Core Business Revenue [high — operational]: Revenues from continuing operations fell to $2.68 million for the six months ended June 30, 2025, down from $3.86 million in the same period of 2024. This 30.6% decrease highlights challenges within the company's primary business segments.
• Significant Increase in Shares Outstanding [medium — financial]: The number of common stock shares outstanding increased from 29,874,029 at December 31, 2024, to 41,541,205 as of August 11, 2025. This substantial dilution could negatively impact existing shareholders' value.
• Net Cash Used in Operations [high — financial]: The company used $4.23 million in net cash for operating activities from continuing operations during the six months ended June 30, 2025. This indicates a continued cash burn, which, coupled with the declining cash balance, presents a significant financial risk.
• Dependence on Discontinued Operations Sale [medium — operational]: The reported net loss improvement from $12.42 million to $0.51 million was primarily driven by an $8.75 million gain from the disposal of discontinued operations (sale of PMI). This reliance on one-time gains masks the ongoing struggles in the core business.
• Reduced Asset Base [medium — financial]: Total assets decreased from $63.20 million at December 31, 2024, to $42.04 million at June 30, 2025. This reduction, partly due to the sale of discontinued operations, signifies a shrinking operational footprint.

Industry Context

ProPhase Labs operates in the diagnostics and biopharma sectors, focusing on areas like pre-cancer screening and whole genome sequencing. This industry is characterized by rapid technological advancements, significant R&D investment, and a complex regulatory environment. Competition comes from established players and emerging biotech firms, with success often depending on innovation, clinical validation, and market adoption.

Regulatory Implications

The company's focus on diagnostics and biopharma means it is subject to stringent regulatory oversight from bodies like the FDA. Compliance with evolving regulations for product development, testing, and marketing is critical. Any delays or failures in regulatory approval processes can significantly impact product launch timelines and market access.

What Investors Should Do

1. Monitor cash burn and liquidity closely.
2. Evaluate the sustainability of revenue from continuing operations.
3. Assess the impact of share dilution.
4. Analyze the strategic rationale and execution of future acquisitions.

Key Dates

• 2025-01-16: Sale of PMI to JL Projects, Inc. — This transaction resulted in an $8.75 million gain from discontinued operations, significantly improving the net loss for the period, but also reducing the company's asset base.
• 2025-06-30: End of Second Quarter — Reported a net loss of $0.51 million and revenues of $2.68 million from continuing operations. Cash and cash equivalents stood at $169,000, and total assets were $42.04 million.
• 2024-12-31: End of Fiscal Year — Reported cash and cash equivalents of $678,000 and total assets of $63.20 million. Common stock shares outstanding were 29,874,029.
• 2025-08-11: Common Stock Shares Outstanding Date — Reported 41,541,205 common stock shares outstanding, indicating significant dilution since the end of the previous fiscal year.

Glossary

Discontinued Operations

A component of a business that the company has disposed of or classified as held for sale, and whose performance is reported separately from continuing operations. (The gain from the sale of ProPhase Labs' discontinued operations significantly impacted the net loss for the period.)

Continuing Operations

The ongoing business activities of a company that are expected to continue into the future. (Revenues from continuing operations declined, highlighting challenges in the company's core business segments.)

Accumulated Deficit

The cumulative net losses of a company since its inception that have not been offset by net income. (ProPhase Labs has a substantial accumulated deficit of $58.899 million as of June 30, 2025, indicating a history of unprofitability.)

Treasury Stock

Stock that a company has repurchased from the open market. (The company holds a significant amount of treasury stock, which reduces total stockholders' equity.)

Warrant Liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (The company recognized a warrant liability of $270,000 as of June 30, 2025.)

Year-Over-Year Comparison

Compared to the prior year period, ProPhase Labs has significantly reduced its net loss from $12.42 million to $0.51 million, largely due to an $8.75 million gain from selling discontinued operations. However, revenues from continuing operations have declined by 30.6% to $2.68 million, signaling weakness in the core business. Total assets have decreased from $63.20 million to $42.04 million, reflecting the sale of assets. The company's cash position has deteriorated sharply, falling from $678,000 to $169,000, while the number of outstanding shares has increased substantially, indicating significant dilution.

Key Financial Figures

• $0.0005 — ich registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate b

Filing Documents

• prph-20250630.htm (10-Q) — 1291KB
• prph-2025630xexx311.htm (EX-31.1) — 11KB
• prph-2025630xexx321.htm (EX-32.1) — 5KB
• 0000868278-25-000011.txt ( ) — 8939KB
• prph-20250630.xsd (EX-101.SCH) — 69KB
• prph-20250630_cal.xml (EX-101.CAL) — 129KB
• prph-20250630_def.xml (EX-101.DEF) — 379KB
• prph-20250630_lab.xml (EX-101.LAB) — 890KB
• prph-20250630_pre.xml (EX-101.PRE) — 630KB
• prph-20250630_htm.xml (XML) — 1149KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of June 30 , 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and S ix Months Ended June 30 , 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30 , 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30 , 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 41 Item 4.

Controls and Procedures

Controls and Procedures 42

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 43 Item 1A.

Risk Factors

Risk Factors 43 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 44 Item 3. Defaults Upon Senior Securities 45 Item 4. Mine Safety Disclosures 45 Item 5. Other Information 45 Item 6. Exhibits 45

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. ProPhase Labs, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 169 $ 678 Marketable securities, available for sale 2 — Accounts receivable, net 20,086 20,058 Inventory, net 830 1,143 Prepaid expenses and other current assets 3,484 2,615 Current assets in discontinued operations — 6,143 Total current assets 24,571 30,637 Property, plant and equipment, net 3,581 7,501 Prepaid expenses, net of current portion 151 217 Operating lease right-of-use asset, net 45 4,115 Intangible assets, net 8,459 9,750 Goodwill 5,231 5,231 Other assets 3 310 Non-current assets in discontinued operations — 5,439 TOTAL ASSETS $ 42,041 $ 63,200 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 15,032 $ 13,717 Accrued diagnostic services 75 31 Accrued advertising and other allowances 151 151 Finance lease liabilities 2,625 2,147 Operating lease liabilities 102 1,214 Short-term loan payable, net of discount of $ 304 and $ 237 2,425 3,207 Short-term loan payable to related party, net of discount of $ 236 389 — Warrant liability 270 — Deferred revenue 1,418 1,698 Income tax payable 1,374 1,987 Other current liabilities 1,765 2,115 Current liabilities in discontinued operations — 5,867 Total current liabilities 25,626 32,134 Non-current liabilities: Unsecured promissory notes, net of discount of $ 127 — 9,873 Unsecured long-term debt, net of discount of $ 216 and $ 423 436 1,779 Due to sellers (see Note 3) 2,000 2,000 3 Deferred revenue, net of current portion 654 784 Operating lease liabilities, net of current portion — 3,762 Finance lease liabilities, net of current portion 1,889 2,591 Non-current liabilities in discontinued operations — 2,924 Total non-current liabilities 4,979 23,713 Total liabilities 30,605 55,847 COMMITMEN

View Full Filing

View this 10-Q filing on SEC EDGAR